ORGANIZATION

October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief

September 25, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The new leader of the umbrella organ of Japanese pharma trade groups has expressed the industry’s opposition to a two-step price tweak in 2019 that the government eyes for the planned consumption tax hike in October that year, pushing for…

To read the full story

FY2019 Revision Should Cover Only “Half a Year’s Worth” of Price Tweaks, MHLW Insurance Chief Says for Clarification
September 3, 2018
April 2019 Price Cut Wouldn’t Fit the Purpose of Tax Tweak: MHLW Insurance Chief
August 31, 2018
MOF Pitching 2-Step Drug Price Tweaks in 2019 Tax Hike Year
May 25, 2018

ORGANIZATION

Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
FPMAJ Calls for Greater Support for Stable Drug Supplies in Honebuto Policy
May 22, 2026
JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
COVID-19 Vaccination Rates Fall as Out-of-Pocket Costs Rise: Jiji Survey
May 21, 2026
Awareness of HPV Vaccination for Males Stands at 39.4%: Survey
May 21, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…